Sequence of radiotherapy and TACE affects the prognosis of HCC with portal vein tumor thrombusNovember 18, 2022Hepatocellular Carcinoma
Atezolizumab+bevacizumab: A better first-line treatment option for unresectable HCC than lenvatinibNovember 18, 2022Hepatocellular Carcinoma
Alpha-fetoprotein and carbohydrate antigen 19-9: Prognostic markers in HCC after hepatectomyNovember 18, 2022Hepatocellular Carcinoma
HAIC+lenvatinib+sequential ablation: An effective and safe treatment option for advanced HCCNovember 18, 2022Hepatocellular Carcinoma
HCC: Atezolizumab+bevacizumab treatment outcome unaffected by the underlying liver etiologyNovember 18, 2022Hepatocellular Carcinoma
Immune checkpoint inhibitor rechallenge is effective and safe in HCCNovember 18, 2022Hepatocellular Carcinoma
Bevacizumab use is questionable in liver cirrhosis with locally advanced HCCNovember 18, 2022Hepatocellular Carcinoma
Advanced HCC: Antidrug antibody levels tied to outcomes in patients on atezolizumab/bevacizumabNovember 18, 2022Hepatocellular Carcinoma
Commentary: Multifocal Hepatocellular Carcinoma, November 2022October 31, 2022Hepatocellular Carcinoma
Alpha-fetoprotein: A real-time monitor in HCC treatment with atezolizumab and bevacizumabOctober 24, 2022Hepatocellular Carcinoma
Unrecognized liver cirrhosis common, associated with worse prognosis in HCCOctober 24, 2022Hepatocellular Carcinoma
Rigorous surveillance recommended after resection for HBV-related HCC in patients with metabolic syndromeOctober 24, 2022Hepatocellular Carcinoma
Blind spots require attention during abdominal ultrasonography-based HCC surveillanceOctober 24, 2022Hepatocellular Carcinoma
Microwave ablation: An alternative to resection in subcapsular HCC within the Milan criteriaOctober 24, 2022Hepatocellular Carcinoma
